The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drugs for Short Bowel Syndrome-Global Market Insights and Sales Trends 2025
Synopsis
The global Drugs for Short Bowel Syndrome market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Short Bowel Syndrome in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Drugs for Short Bowel Syndrome market. GLP-2, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Growth Hormone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Short Bowel Syndrome, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Short Bowel Syndrome market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Short Bowel Syndrome market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Short Bowel Syndrome sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Short Bowel Syndrome covered in this report include Ardelyx, Emmaus Life Sciences, GLyPharma Therapeutic, Merck, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio & Company and Takeda, etc.
The global Drugs for Short Bowel Syndrome market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ardelyx
Emmaus Life Sciences
GLyPharma Therapeutic
Merck
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio & Company
Takeda
Zealand Pharma
Global Drugs for Short Bowel Syndrome market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Short Bowel Syndrome market, Segment by Type:
GLP-2
Growth Hormone
Glutamine
Other
Global Drugs for Short Bowel Syndrome market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Short Bowel Syndrome companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Drugs for Short Bowel Syndrome market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Short Bowel Syndrome in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Drugs for Short Bowel Syndrome market. GLP-2, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Growth Hormone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Short Bowel Syndrome, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Short Bowel Syndrome market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Short Bowel Syndrome market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Short Bowel Syndrome sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Short Bowel Syndrome covered in this report include Ardelyx, Emmaus Life Sciences, GLyPharma Therapeutic, Merck, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio & Company and Takeda, etc.
The global Drugs for Short Bowel Syndrome market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ardelyx
Emmaus Life Sciences
GLyPharma Therapeutic
Merck
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio & Company
Takeda
Zealand Pharma
Global Drugs for Short Bowel Syndrome market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Short Bowel Syndrome market, Segment by Type:
GLP-2
Growth Hormone
Glutamine
Other
Global Drugs for Short Bowel Syndrome market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Short Bowel Syndrome companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Drugs for Short Bowel Syndrome
1.1 Drugs for Short Bowel Syndrome Market Overview
1.1.1 Drugs for Short Bowel Syndrome Product Scope
1.1.2 Drugs for Short Bowel Syndrome Market Status and Outlook
1.2 Global Drugs for Short Bowel Syndrome Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drugs for Short Bowel Syndrome Market Size by Region (2018-2029)
1.4 Global Drugs for Short Bowel Syndrome Historic Market Size by Region (2018-2023)
1.5 Global Drugs for Short Bowel Syndrome Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drugs for Short Bowel Syndrome Market Size (2018-2029)
1.6.1 North America Drugs for Short Bowel Syndrome Market Size (2018-2029)
1.6.2 Europe Drugs for Short Bowel Syndrome Market Size (2018-2029)
1.6.3 Asia-Pacific Drugs for Short Bowel Syndrome Market Size (2018-2029)
1.6.4 Latin America Drugs for Short Bowel Syndrome Market Size (2018-2029)
1.6.5 Middle East & Africa Drugs for Short Bowel Syndrome Market Size (2018-2029)
2 Drugs for Short Bowel Syndrome Market by Type
2.1 Introduction
2.1.1 GLP-2
2.1.2 Growth Hormone
2.1.3 Glutamine
2.1.4 Other
2.2 Global Drugs for Short Bowel Syndrome Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drugs for Short Bowel Syndrome Historic Market Size by Type (2018-2023)
2.2.2 Global Drugs for Short Bowel Syndrome Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drugs for Short Bowel Syndrome Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drugs for Short Bowel Syndrome Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drugs for Short Bowel Syndrome Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drugs for Short Bowel Syndrome Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drugs for Short Bowel Syndrome Revenue Breakdown by Type (2018-2029)
3 Drugs for Short Bowel Syndrome Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Drugs for Short Bowel Syndrome Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drugs for Short Bowel Syndrome Historic Market Size by Application (2018-2023)
3.2.2 Global Drugs for Short Bowel Syndrome Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drugs for Short Bowel Syndrome Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drugs for Short Bowel Syndrome Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drugs for Short Bowel Syndrome Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drugs for Short Bowel Syndrome Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drugs for Short Bowel Syndrome Revenue Breakdown by Application (2018-2029)
4 Drugs for Short Bowel Syndrome Competition Analysis by Players
4.1 Global Drugs for Short Bowel Syndrome Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Short Bowel Syndrome as of 2022)
4.3 Date of Key Players Enter into Drugs for Short Bowel Syndrome Market
4.4 Global Top Players Drugs for Short Bowel Syndrome Headquarters and Area Served
4.5 Key Players Drugs for Short Bowel Syndrome Product Solution and Service
4.6 Competitive Status
4.6.1 Drugs for Short Bowel Syndrome Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Ardelyx
5.1.1 Ardelyx Profile
5.1.2 Ardelyx Main Business
5.1.3 Ardelyx Drugs for Short Bowel Syndrome Products, Services and Solutions
5.1.4 Ardelyx Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.1.5 Ardelyx Recent Developments
5.2 Emmaus Life Sciences
5.2.1 Emmaus Life Sciences Profile
5.2.2 Emmaus Life Sciences Main Business
5.2.3 Emmaus Life Sciences Drugs for Short Bowel Syndrome Products, Services and Solutions
5.2.4 Emmaus Life Sciences Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.2.5 Emmaus Life Sciences Recent Developments
5.3 GLyPharma Therapeutic
5.3.1 GLyPharma Therapeutic Profile
5.3.2 GLyPharma Therapeutic Main Business
5.3.3 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Products, Services and Solutions
5.3.4 GLyPharma Therapeutic Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Recent Developments
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business
5.4.3 Merck Drugs for Short Bowel Syndrome Products, Services and Solutions
5.4.4 Merck Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Recent Developments
5.5 Naia Pharmaceuticals
5.5.1 Naia Pharmaceuticals Profile
5.5.2 Naia Pharmaceuticals Main Business
5.5.3 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Products, Services and Solutions
5.5.4 Naia Pharmaceuticals Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.5.5 Naia Pharmaceuticals Recent Developments
5.6 Nutrinia
5.6.1 Nutrinia Profile
5.6.2 Nutrinia Main Business
5.6.3 Nutrinia Drugs for Short Bowel Syndrome Products, Services and Solutions
5.6.4 Nutrinia Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.6.5 Nutrinia Recent Developments
5.7 OxThera
5.7.1 OxThera Profile
5.7.2 OxThera Main Business
5.7.3 OxThera Drugs for Short Bowel Syndrome Products, Services and Solutions
5.7.4 OxThera Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.7.5 OxThera Recent Developments
5.8 Sancilio & Company
5.8.1 Sancilio & Company Profile
5.8.2 Sancilio & Company Main Business
5.8.3 Sancilio & Company Drugs for Short Bowel Syndrome Products, Services and Solutions
5.8.4 Sancilio & Company Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.8.5 Sancilio & Company Recent Developments
5.9 Takeda
5.9.1 Takeda Profile
5.9.2 Takeda Main Business
5.9.3 Takeda Drugs for Short Bowel Syndrome Products, Services and Solutions
5.9.4 Takeda Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.9.5 Takeda Recent Developments
5.10 Zealand Pharma
5.10.1 Zealand Pharma Profile
5.10.2 Zealand Pharma Main Business
5.10.3 Zealand Pharma Drugs for Short Bowel Syndrome Products, Services and Solutions
5.10.4 Zealand Pharma Drugs for Short Bowel Syndrome Revenue (US$ Million) & (2018-2023)
5.10.5 Zealand Pharma Recent Developments
6 North America
6.1 North America Drugs for Short Bowel Syndrome Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Drugs for Short Bowel Syndrome Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Short Bowel Syndrome Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drugs for Short Bowel Syndrome Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Short Bowel Syndrome Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drugs for Short Bowel Syndrome Market Dynamics
11.1 Drugs for Short Bowel Syndrome Industry Trends
11.2 Drugs for Short Bowel Syndrome Market Drivers
11.3 Drugs for Short Bowel Syndrome Market Challenges
11.4 Drugs for Short Bowel Syndrome Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
